Multimodale Therapie bei Karzinomen des gastroösophagealen Übergangs (GÖÜ) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-09

AUTHORS

Sylvie Lorenzen, Katja Ott, Florian Lordick

ABSTRACT

The incidence of gastroesophageal-junction cancers is rapidly increasing in the Western hemisphere and this disease is among the leading causes of cancer- related deaths in the world. The prognosis of locally advanced gastric and esophageal cancers is poor, with high rates of both local and distant relapse and a 5-year survival rate of only 20–30%. It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone. Two randomized studies that have been performed in Europe have shown Adenothat perioperative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and the gastroesophageal junction. Due to the results of recent meta-analyses, patients with locally advanced adenocarcinomas of the esophagus receive neoadjuvant chemotherapy or chemoradiation therapy. In addition to standard perioperative chemotherapy, novel targeted agents such as bevacizumab, cetuximab and panitumumab are currently being evaluated in clinical trials to determine their role in the management of resectable gastroesophageal cancers.In spite of the promising results obtained with multimodal treatment strategies, a good portion of patients still gets an ineffective and toxic treatment. Positron emission tomography imaging with the glucose analog [18F]-fluorodeoxyglucose (FDG-PET) may allow to predict tumor response and patient outcome very early in the course of therapy by quantitative assessment of therapy-induced changes in tumor FDG uptake. This suggests that FDG-PET can identify particularly patients who do not respond to neoadjuvant therapy, allowing for early modifications of the treatment protocol. More... »

PAGES

92

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s15035-009-0159-7

DOI

http://dx.doi.org/10.1007/s15035-009-0159-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035202672


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medizinische Onkologie, Nationales Centrum f\u00fcr Tumorerkrankungen (NCT), Im Neuenheimer Feld 350, 69120, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461742.2", 
          "name": [
            "Medizinische Onkologie, Nationales Centrum f\u00fcr Tumorerkrankungen, Universit\u00e4t Heidelberg, Heidelberg, Germany", 
            "Medizinische Onkologie, Nationales Centrum f\u00fcr Tumorerkrankungen (NCT), Im Neuenheimer Feld 350, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lorenzen", 
        "givenName": "Sylvie", 
        "id": "sg:person.01044431427.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044431427.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chirurgische Klinik, Universit\u00e4t Heidelberg, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Chirurgische Klinik, Universit\u00e4t Heidelberg, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ott", 
        "givenName": "Katja", 
        "id": "sg:person.01214055342.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214055342.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik III, Klinikum Braunschweig, Braunschweig, Germany", 
          "id": "http://www.grid.ac/institutes/grid.419806.2", 
          "name": [
            "Medizinische Klinik III, Klinikum Braunschweig, Braunschweig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lordick", 
        "givenName": "Florian", 
        "id": "sg:person.01242313310.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242313310.55"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-09", 
    "datePublishedReg": "2009-09-01", 
    "description": "The incidence of gastroesophageal-junction cancers is rapidly increasing in the Western hemisphere and this disease is among the leading causes of cancer- related deaths in the world. The prognosis of locally advanced gastric and esophageal cancers is poor, with high rates of both local and distant relapse and a 5-year survival rate of only 20\u201330%. It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone. Two randomized studies that have been performed in Europe have shown Adenothat perioperative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and the gastroesophageal junction. Due to the results of recent meta-analyses, patients with locally advanced adenocarcinomas of the esophagus receive neoadjuvant chemotherapy or chemoradiation therapy. In addition to standard perioperative chemotherapy, novel targeted agents such as bevacizumab, cetuximab and panitumumab are currently being evaluated in clinical trials to determine their role in the management of resectable gastroesophageal cancers.In spite of the promising results obtained with multimodal treatment strategies, a good portion of patients still gets an ineffective and toxic treatment. Positron emission tomography imaging with the glucose analog [18F]-fluorodeoxyglucose (FDG-PET) may allow to predict tumor response and patient outcome very early in the course of therapy by quantitative assessment of therapy-induced changes in tumor FDG uptake. This suggests that FDG-PET can identify particularly patients who do not respond to neoadjuvant therapy, allowing for early modifications of the treatment protocol.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s15035-009-0159-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1045990", 
        "issn": [
          "1866-5861", 
          "1866-587X"
        ], 
        "name": "Onkopipeline", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "perioperative chemotherapy", 
      "therapy-induced changes", 
      "cancer-related death", 
      "resectable gastroesophageal cancer", 
      "tumor FDG uptake", 
      "survival of patients", 
      "FDG-PET", 
      "multimodal treatment strategies", 
      "course of therapy", 
      "positron emission tomography", 
      "distant relapse", 
      "neoadjuvant chemotherapy", 
      "neoadjuvant therapy", 
      "advanced gastric", 
      "advanced adenocarcinoma", 
      "chemoradiation therapy", 
      "gastroesophageal cancer", 
      "gastroesophageal junction", 
      "FDG uptake", 
      "multimodal treatment", 
      "tumor response", 
      "esophageal cancer", 
      "clinical trials", 
      "treatment strategies", 
      "patient outcomes", 
      "treatment protocol", 
      "toxic treatment", 
      "survival rate", 
      "patients", 
      "emission tomography", 
      "chemotherapy", 
      "therapy", 
      "cancer", 
      "glucose analog", 
      "adenocarcinoma", 
      "early modifications", 
      "high rate", 
      "outcomes", 
      "treatment", 
      "panitumumab", 
      "relapse", 
      "cetuximab", 
      "quantitative assessment", 
      "prognosis", 
      "esophagus", 
      "gastric", 
      "incidence", 
      "disease", 
      "stomach", 
      "trials", 
      "death", 
      "survival", 
      "tomography", 
      "promising results", 
      "cause", 
      "rate", 
      "agents", 
      "Western Hemisphere", 
      "course", 
      "response", 
      "assessment", 
      "uptake", 
      "management", 
      "hemisphere", 
      "study", 
      "role", 
      "protocol", 
      "results", 
      "changes", 
      "junctions", 
      "spite", 
      "analogues", 
      "addition", 
      "portion", 
      "strategies", 
      "\u00dcbergang", 
      "comparison", 
      "modification", 
      "good portion", 
      "Europe", 
      "world", 
      "gastroesophageal-junction cancers", 
      "Adenothat perioperative chemotherapy", 
      "standard perioperative chemotherapy", 
      "Multimodale Therapie bei Karzinomen", 
      "Therapie bei Karzinomen", 
      "bei Karzinomen", 
      "Karzinomen", 
      "gastro\u00f6sophagealen \u00dcbergangs"
    ], 
    "name": "Multimodale Therapie bei Karzinomen des gastro\u00f6sophagealen \u00dcbergangs (G\u00d6\u00dc)", 
    "pagination": "92", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035202672"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s15035-009-0159-7"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s15035-009-0159-7", 
      "https://app.dimensions.ai/details/publication/pub.1035202672"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_491.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s15035-009-0159-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s15035-009-0159-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s15035-009-0159-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s15035-009-0159-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s15035-009-0159-7'


 

This table displays all metadata directly associated to this object as RDF triples.

172 TRIPLES      21 PREDICATES      116 URIs      107 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s15035-009-0159-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1112
4 schema:author N9d81985c384e4a0cb8d1cf438c8fb201
5 schema:datePublished 2009-09
6 schema:datePublishedReg 2009-09-01
7 schema:description The incidence of gastroesophageal-junction cancers is rapidly increasing in the Western hemisphere and this disease is among the leading causes of cancer- related deaths in the world. The prognosis of locally advanced gastric and esophageal cancers is poor, with high rates of both local and distant relapse and a 5-year survival rate of only 20–30%. It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone. Two randomized studies that have been performed in Europe have shown Adenothat perioperative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and the gastroesophageal junction. Due to the results of recent meta-analyses, patients with locally advanced adenocarcinomas of the esophagus receive neoadjuvant chemotherapy or chemoradiation therapy. In addition to standard perioperative chemotherapy, novel targeted agents such as bevacizumab, cetuximab and panitumumab are currently being evaluated in clinical trials to determine their role in the management of resectable gastroesophageal cancers.In spite of the promising results obtained with multimodal treatment strategies, a good portion of patients still gets an ineffective and toxic treatment. Positron emission tomography imaging with the glucose analog [18F]-fluorodeoxyglucose (FDG-PET) may allow to predict tumor response and patient outcome very early in the course of therapy by quantitative assessment of therapy-induced changes in tumor FDG uptake. This suggests that FDG-PET can identify particularly patients who do not respond to neoadjuvant therapy, allowing for early modifications of the treatment protocol.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N3520a660928a404fac9936a0b553204a
12 Nb7ca41c52e6843619ae01f5a05a32994
13 sg:journal.1045990
14 schema:keywords Adenothat perioperative chemotherapy
15 Europe
16 FDG uptake
17 FDG-PET
18 Karzinomen
19 Multimodale Therapie bei Karzinomen
20 Therapie bei Karzinomen
21 Western Hemisphere
22 addition
23 adenocarcinoma
24 advanced adenocarcinoma
25 advanced gastric
26 agents
27 analogues
28 assessment
29 bei Karzinomen
30 cancer
31 cancer-related death
32 cause
33 cetuximab
34 changes
35 chemoradiation therapy
36 chemotherapy
37 clinical trials
38 comparison
39 course
40 course of therapy
41 death
42 disease
43 distant relapse
44 early modifications
45 emission tomography
46 esophageal cancer
47 esophagus
48 gastric
49 gastroesophageal cancer
50 gastroesophageal junction
51 gastroesophageal-junction cancers
52 gastroösophagealen Übergangs
53 glucose analog
54 good portion
55 hemisphere
56 high rate
57 incidence
58 junctions
59 management
60 modification
61 multimodal treatment
62 multimodal treatment strategies
63 neoadjuvant chemotherapy
64 neoadjuvant therapy
65 outcomes
66 panitumumab
67 patient outcomes
68 patients
69 perioperative chemotherapy
70 portion
71 positron emission tomography
72 prognosis
73 promising results
74 protocol
75 quantitative assessment
76 rate
77 relapse
78 resectable gastroesophageal cancer
79 response
80 results
81 role
82 spite
83 standard perioperative chemotherapy
84 stomach
85 strategies
86 study
87 survival
88 survival of patients
89 survival rate
90 therapy
91 therapy-induced changes
92 tomography
93 toxic treatment
94 treatment
95 treatment protocol
96 treatment strategies
97 trials
98 tumor FDG uptake
99 tumor response
100 uptake
101 world
102 Übergang
103 schema:name Multimodale Therapie bei Karzinomen des gastroösophagealen Übergangs (GÖÜ)
104 schema:pagination 92
105 schema:productId N6845c3fdafe24a0abb63ac14cf71cb9b
106 Neceddb1c75c54dbba1ac694b1e30917d
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035202672
108 https://doi.org/10.1007/s15035-009-0159-7
109 schema:sdDatePublished 2021-12-01T19:22
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N9222e06bc19d450893a4811156797347
112 schema:url https://doi.org/10.1007/s15035-009-0159-7
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N3520a660928a404fac9936a0b553204a schema:issueNumber 3
117 rdf:type schema:PublicationIssue
118 N3790f8d72edc469592d8c57360c7d593 rdf:first sg:person.01242313310.55
119 rdf:rest rdf:nil
120 N411f416e296e451592bac2578d984c38 rdf:first sg:person.01214055342.00
121 rdf:rest N3790f8d72edc469592d8c57360c7d593
122 N6845c3fdafe24a0abb63ac14cf71cb9b schema:name dimensions_id
123 schema:value pub.1035202672
124 rdf:type schema:PropertyValue
125 N9222e06bc19d450893a4811156797347 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N9d81985c384e4a0cb8d1cf438c8fb201 rdf:first sg:person.01044431427.33
128 rdf:rest N411f416e296e451592bac2578d984c38
129 Nb7ca41c52e6843619ae01f5a05a32994 schema:volumeNumber 2
130 rdf:type schema:PublicationVolume
131 Neceddb1c75c54dbba1ac694b1e30917d schema:name doi
132 schema:value 10.1007/s15035-009-0159-7
133 rdf:type schema:PropertyValue
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
138 schema:name Clinical Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
141 schema:name Oncology and Carcinogenesis
142 rdf:type schema:DefinedTerm
143 sg:journal.1045990 schema:issn 1866-5861
144 1866-587X
145 schema:name Onkopipeline
146 schema:publisher Springer Nature
147 rdf:type schema:Periodical
148 sg:person.01044431427.33 schema:affiliation grid-institutes:grid.461742.2
149 schema:familyName Lorenzen
150 schema:givenName Sylvie
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044431427.33
152 rdf:type schema:Person
153 sg:person.01214055342.00 schema:affiliation grid-institutes:None
154 schema:familyName Ott
155 schema:givenName Katja
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214055342.00
157 rdf:type schema:Person
158 sg:person.01242313310.55 schema:affiliation grid-institutes:grid.419806.2
159 schema:familyName Lordick
160 schema:givenName Florian
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242313310.55
162 rdf:type schema:Person
163 grid-institutes:None schema:alternateName Chirurgische Klinik, Universität Heidelberg, Heidelberg, Germany
164 schema:name Chirurgische Klinik, Universität Heidelberg, Heidelberg, Germany
165 rdf:type schema:Organization
166 grid-institutes:grid.419806.2 schema:alternateName Medizinische Klinik III, Klinikum Braunschweig, Braunschweig, Germany
167 schema:name Medizinische Klinik III, Klinikum Braunschweig, Braunschweig, Germany
168 rdf:type schema:Organization
169 grid-institutes:grid.461742.2 schema:alternateName Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen (NCT), Im Neuenheimer Feld 350, 69120, Heidelberg, Germany
170 schema:name Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen (NCT), Im Neuenheimer Feld 350, 69120, Heidelberg, Germany
171 Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen, Universität Heidelberg, Heidelberg, Germany
172 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...